GT Biopharma, Inc.
GT Biopharma, Inc. (GTBP): 37 pipeline candidates · 19 upcoming catalysts · ~11 mo cash runway · 35 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.3 months
0% dilution
Lead: Approved
37 candidates
19 upcoming, next in ~30d
N/A
A transparent, data-derived signal for GT Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$16.2M
Cash
$9.0M
Quarterly Burn
$2.5M
Runway
11.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (37 candidates)
| Drug | Phase |
|---|---|
| acetaminophen | Approved |
| adalimumab | Phase 3 |
| anti-cd20 antibodies | Phase 3 |
| azithromycin | Approved |
| bepranemab | Phase 2 |
| bimekizumab | Phase 3 |
| dapirolizumab pegol | Phase 3 |
| dzp | Phase 3 |
| eculizumab | Phase 3 |
| fingolimod | Approved |
Showing 10 of 37 candidates. Sign up for full pipeline.
Upcoming Catalysts (19)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$715K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 903,750 | $369K |
| geode capital management, llc | 294,459 | $120K |
| vanguard fiduciary trust co | 225,938 | $92K |
| citadel advisors llc | 66,165 | $27K |
| two sigma securities, llc | 31,796 | $13K |
| osaic holdings, inc. | 21,000 | $9K |
| cerity partners llc | 20,023 | $8K |
| integrated wealth concepts llc | 20,006 | $8K |
| private wealth management group, llc | 20,000 | $8K |
| morgan stanley | 16,599 | $7K |
Showing top 10 of 36 institutional holders of GT Biopharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GT Biopharma, Inc.'s pipeline?
GT Biopharma, Inc. (GTBP) has 37 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GT Biopharma, Inc.'s lead drug candidate?
GT Biopharma, Inc.'s most advanced tracked candidate is acetaminophen (Approved) for Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis.
What is GT Biopharma, Inc.'s next catalyst?
GT Biopharma, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DUEXIS" — expected July 18, 2026.
What is GT Biopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GT Biopharma, Inc. has approximately 11.3 months of cash runway.
What is GT Biopharma, Inc.'s market capitalization?
GT Biopharma, Inc.'s market capitalization is approximately $16.2M.
Get the full picture on GT Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.